CEO concerned that Wall Street reporter’s inaccurate reports are becoming a safety issue (NASDAQ:OCLS) (NASDAQ:TSCM)
Pasadena, CA - 06/29/09 - BioMedReports.Com, the news portal covering the biomedical sector that delivers financial and investment intelligence to a community of highly informed investors has conducted an exclusive interview with Hoji Alimi, CEO, President and Founder of Oculus Innovative Sciences(NASDAQ:OCLS).
In it, Mr Alimi responds to an article by Adam Feuerstein of TheStreet.Com (NASDAQ:TSCM) which reported that Mr. Alimi’s company “appeared to be skirting U.S. drug laws by claiming that its wound-cleansing product containing common diluted bleach has drug-like therapeutic properties.”
“This is becoming a patient safety issue and putting public safety at risk,” Alimi tells BioMedReports during the recorded interview. “It’s no longer [about] attacking a company and the market potential and market cap. You’re damaging public safety.”
“When you haven’t done your due diligence and you don’t understand the basic chemistry of our product [and] you make recommendations like that you are putting patients’ safety at risk,” insists Alimi. “There has to be a level of integrity in the research written and I think that’s really lacking in their case.”
Investors are invited to listen to the interview at BioMedReports.Com
Biotech investors interested in seeing the complete database of clinical trials and upcoming FDA decisions can access that information here:
Disclosure: No positions.
BioMedReports.com is a news portal covering the biomedical news and financial sector. It features its own blog, discussion forum, stock research reports, news feeds, videos, press release capability, stock commentaries, and other unique content - including FDA and Clinical Trial Calendars plus a database that includes about 1,000 stocks and exchange-traded funds from the healthcare sector which are organized into various new healthcare stock indexes.
For more biomedical sector and investment news, go to www.BioMedReports.com
Certain sections of this report contain forward-looking statements that are based on our reporters’ expectations, estimates, projections and assumptions. Words such as “expects” “anticipates” “plans” “believes” “scheduled” “estimates” and variations of these words and similar expressions are intended to identify forward-looking statements, which include but are not limited to projections of revenues, earnings, segment performance, cash flows, contract awards, FDA announcements, trial and drug approvals, and company stability. Forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, as amended. These statements are not guarantees of future performance and involve certain risks and uncertainties, which are difficult to predict. Therefore, actual future results and trends may differ materially from what is forecast in forward-looking statements due to a variety of factors including but not limited to the status or outcome of legal and/or regulatory proceedings.
All forward-looking statements speak only as of the date of this report or, in the case of any document incorporated by reference, the date of that document. All subsequent written and oral forward-looking statements attributable to the company or any person acting on the company’s behalf are qualified by the cautionary statements in this section. BiomedReports.Com does not undertake any obligation to update or publicly release any revisions to forward-looking statements to reflect events, circumstances or changes in expectations after the date of this report.
- Contact Information
- M.E. Garza
- Contact via E-mail
This news content may be integrated into any legitimate news gathering and publishing effort. Linking is permitted.
News Release Distribution and Press Release Distribution Services Provided by WebWire.